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Immunotherapies targeting tau in mouse models of human tauopathies could have disease-modifying
effects. In this issue of Neuron, Yanamandra et al. (2013) use tau antibodies, which effectively block tau
seeding in culture, to attenuate tauopathy and improve cognition in mutant tau mouse models.Alzheimer’s disease (AD) is pathologically
characterized by the presence of both
extracellular Ab deposits and intracellular
deposits of tau in the brain. Multiple lines
of evidence indicate that accumulation
and aggregation of both proteins plays a
pivotal role in disease, and thus both Ab
and tau have been the primary foci of
efforts to develop disease-modifying
therapies for AD. Tau inclusion pathology
also is the primary pathological hallmark
of several other neurodegenerative disor-
ders such as progressive supranuclear
palsy and Pick’s disease. In addition,
mutations in tau that result in neurofibril-
lary pathology and neurodegeneration
can cause FTLD-17t. Thus, tau is a major
therapeutic target in AD and in neurode-
generative diseases that are collectively
referred to as tauopathies.
Following the pioneering preclinical
studies by Schenk and colleagues
demonstrating the preclinical efficacy of
active and passive immunotherapy tar-
geting Ab, there has been increasing
interest in developing immunotherapies
to treat AD and other neurodegenerative
proteinopathies including human tauopa-
thies. Though many questions remain
regarding mechanisms of action of anti-
Ab immunotherapies and optimal trial
design to evaluate efficacy in humans,
there has been rapid advancement of
these therapies into human trials (Golde
et al., 2009), although initial therapeutic
trials have not shown significant evidence
for efficacy in humans with mild to moder-
ate AD (Golde et al., 2011).
Following peripheral antibody adminis-
tration, only a small fraction is found in
the brain (0.1% of the serum levels).
Thus, initial Ab immunotherapy studies
were met with some skepticism regard-
ing how such a small amount of antibody254 Neuron 80, October 16, 2013 ª2013 Elsecould have robust effects on brain Ab
deposition. Nevertheless, because Ab is
a normally secreted protein and primarily
deposits outside of cells in the brain
parenchyma, the concept that an anti-
Ab antibody present at low levels in the
brain interstitial fluid could affect Ab
deposition was at least partly accepted
by the field. In contrast, when proof-of-
concept studies emerged suggesting
that active and passive anti-tau immu-
notherapy might also attenuate tau
pathology in mouse models, there was
substantial skepticism of how extracel-
lular anti-tau antibodies could target
intracellular tau inclusions (reviewed in
Gu and Sigurdsson, 2011). Moreover,
given the variance in degree of patho-
logy in tau mouse models and the
rather modest effects seen in initial
studies, skepticism remained regarding
the potential therapeutic utility of anti-
tau immunotherapy.
In the current study, Yanamandra et al.
(2013) provide in vivo preclinical data in
a P301S mouse model of tauopathy
showing that direct chronic infusion of
select anti-tau antibodies is efficacious.
Not only did select tau antibodies sup-
press tau pathology, they also improved
cognitive function. Moreover, by selecting
tau antibodies based on their empirical
ability to block exogenous seeding of
tau inclusions in cell culture, Yanamandra
et al. (2013) established a method to
rapidly identify potentially efficacious
antibodies for in vivo testing. The most
effective antibodies in vitro were also the
most effective at attenuating pathology
in vivo. This is important as it supports
Yanamandra et al. (2013)’s assertion that
the most likely mechanism of action is
targeting tau released from cells (see
Figure 1) that is potentially capable ofvier Inc.nucleating pathology in neighboring cells
(Frost et al., 2009).
As Yanamandra et al. (2013) discuss,
there are other plausible mechanisms by
which anti-tau antibodies could attenuate
pathology and additional study will be
important. For example, if an antibody-
tau complex gains entry to the cell or
the antibody gains entry and then binds
intracellular tau, the complex could be
recognized by TRIM21—a protein that
contains the highest affinity IgG heavy
chain (Fc) binding domain of any mam-
malian protein and a ubiquitin ligase
domain (McEwan et al., 2011)—thus
targeting the complex for degradation
by the proteosome. There is also evi-
dence that neurons have Fc receptors,
which could play a role in internaliza-
tion of tau antibodies (Mohamed et al.,
2002). Although Yanamandra et al.
(2013) did not detect intraneuronal anti-
tau IgGs, others have reported the pres-
ence of tau antibodies in neurons
following immunotherapy.
If, as the current data would strongly
suggest, anti-tau antibodies bind extra-
cellular tau and block uptake of seeding-
competent tau assemblies into the cell,
then there are several interrelated and
therapeutically relevant issues that need
further clarification. For instance, why
does antibody engagement of extra-
cellular tau block its ability to seed
intracellular inclusion pathology? It is not
clear why those antibodies most effec-
tive at blocking tau seeding in culture
were also the most effective antibodies
in vivo. The most effective antibodies
may be those that effectively bind the
form of tau that is most capable of seed-
ing. However, as no one has identified the
precise structural nature of the ‘‘seed’’ for
any protein that promotes pathological
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Figure 1. Model of Tau Seeding and Effects of Immunotherapy
Exogenous pathological tau, presumably released from neurons, ‘‘seeds’’ formation of tau aggregates in
other neurons and induces an inflammatory response (activated microglia and astrocytes), thereby prop-
agating neuropathology. Anti-tau antibodies probably bind to exogenous pathological tau (including fi-
brils) and prevent both ‘‘seeding’’ and non-cell-autonomous neuroimmune response. The degree to which
anti-tau antibodies might also get into neurons and affect spread of tau pathology is not represented here
but should be considered.
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tion remains unproven. Interestingly, all of
the anti-tau antibodies in the current
study with in vivo efficacy also had high
affinity for tau and bound distinct linear
epitopes, suggesting that they do not
bind specific tau conformers responsible
for seeding. This is potentially important
as evidence emerges that many amyloid
proteins may have specific conformers
or strains, which might limit efficacy of a
conformation-specific antibody.
The fate of the anti-tau antibody tau
complex is also unclear. There are two
likely, nonexclusive possibilities: the
complex is rapidly exported from the
brain to the plasma, as has been
observed for anti-Ab antibody-Ab com-
plexes; or it binds to microglial FcR and
is subsequently degraded by these cells(Levites et al., 2006; Schenk et al., 1999).
If an antibody-tau complex formed in the
CNS can be detected in the plasma,
this would be a major advance as it
would provide a peripheral marker for
target engagement of a tau-based
immunotherapy.
The relative contribution of seeding
to other mechanisms underlying tau
pathology is also an unexplored issue.
As discussed in a recent review, ‘‘spread’’
of inclusion pathology in CNS proteinopa-
thies is likely to result from a combination
of mechanisms that includes cell-autono-
mous intrinsic disruption of proteostasis
and two non-cell-autonomous mecha-
nisms—seeding from extracellular tau
and induction of a toxic environment
induced either by extracellular tau acting
as an inflammogen or by a response toNeuron 80intracellular inclusion pathology that
could promote aggregate formation
(Golde et al., 2013). Unless tau antibodies
actually do target tau directly in the cell,
an anti-tau antibody would presumably
only target the non-cell-autonomous
mechanisms. Though animal modeling
data suggest that non-cell-autonomous
seeding may play a major role in spread
in some mouse tauopathy models (de
Calignon et al., 2012; Liu et al., 2012),
the extent to which it contributes to
spread in human tauopathies is unknown.
If in humans, as suggested by spatiotem-
poral progression of tau pathology, seed-
ing is a major pathway of pathology
spread (Braak and Braak, 1991), then
tau antibodies should prove effective. If
the majority of pathology develops via
an intrinsic disruption of proteostasis or
a toxic environment that is independent
of extracellular tau, then tau immunother-
apies may prove less effective.
One of the nuances of the current study
is that the antibodies were chronically
infused into the ventricles by osmotic
pumps. Yanamandra et al. (2013) de-
signed the infusions to produce CNS anti-
body levels similar to what are achieved
following peripheral dosing studies,
thereby circumventing the issue of low
levels of antibody getting into the CNS.
All antibodies almost certainly cycle be-
tween the plasma into CNS and rapid
cycling can result in reasonably high
CNS exposure of the total antibody dosed
(Golde et al., 2009). Thus, tau may be a
better target for peripheral immuno-
therapy then Ab. Unlike Ab, tau is present
at undetectable levels in plasma; thus,
there is no significant peripheral pool of
tau to bind to the antibody before it rea-
ches its target in the CNS. In addition,
the levels of extracellular interstitial fluid
and CSF tau are quite low relative to Ab
(Yamada et al., 2011). Even small
amounts of antibody could significantly
deplete this pool.
Irrespective of whether the antibodies
work when injected peripherally, it is
important to consider that direct cerebral
administration of antibodies may have
potential benefits. Direct infusion would
obviate concerns about insufficient CNS
exposure. For clinical use, direct infusion
would likely dramatically reduce the
amount of antibody needed, reducing
the cost of therapy and potentially limiting, October 16, 2013 ª2013 Elsevier Inc. 255
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jected antibody. The potential benefits
of direct infusion, however, must be
weighed against the invasiveness of the
technique. Issues such as timing, dura-
tion, and frequency of dosing, as well as
safety and tolerability, could critically
impact the feasibility of direct administra-
tion. Delivery issues will need to be
resolved for such therapy to be viable
and available to our ever increasing
patient population.
The current study will likely bolster
ongoing efforts to rapidly move tau
immunotherapy toward human trials. The
screen developed by Yanamandra et al.
(2013) to identify antibodies capable of
blocking tau seeding may be transforma-
tive, as it provides a method to rapidly
select antibodies most likely to work
in vivo. A remaining challenge is the
ability of tau immunotherapy to alter
tau-induced neurodegenerative changes.
Given the huge expense associated with
AD therapeutics trials and additional
expenses incurred when using a biolog-
ical therapy, it may be well warranted
to thoroughly evaluate such immuno-
therapy in multiple preclinical models
before rushing to the clinic. Though
many would argue that tau dysfunction
and pathology is a secondary but
extremely important ‘‘hit’’ in AD, whether
there is a true temporal distinction be-256 Neuron 80, October 16, 2013 ª2013 Elsetween Ab accumulation and tau dysfunc-
tion in human brain is still a subject of
great debate. Thus, the field should be
cautious and ensure that trial design for
future anti-tau immunotherapies matches
the situations in which preclinical studies
show significant efficacy. As there is no
clear-cut road map for assessing cogni-
tive or functional changes in the preclini-
cal stages of AD, future clinical studies
will need to incorporate biomarkers to
track target engagement and provide
early indicators of possible therapeutic
efficacy. The recent development of
imaging-based biomarkers that track the
progression of tau pathology in living
patients should greatly facilitate the early
phase testing of tau immunotherapies
and other tau-targeting therapeutics
(Maruyama et al., 2013).REFERENCES
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